Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742
作者:Wensheng Yu、Craig A. Coburn、Anilkumar G. Nair、Michael Wong、Ling Tong、Michael P. Dwyer、Bin Hu、Bin Zhong、Jinglai Hao、De-Yi Yang、Oleg Selyutin、Yueheng Jiang、Stuart B. Rosenblum、Seong Heon Kim、Brian J. Lavey、Guowei Zhou、Razia Rizvi、Bandarpalle B. Shankar、Qingbei Zeng、Lei Chen、Sony Agrawal、Donna Carr、Laura Rokosz、Rong Liu、Stephanie Curry、Patricia McMonagle、Paul Ingravallo、Fred Lahser、Ernest Asante-Appiah、Amin Nomeir、Joseph A. Kozlowski
DOI:10.1016/j.bmcl.2016.05.041
日期:2016.8
HCVNS5Ainhibitors have demonstrated impressive in vitro potency profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed dose combination regimen for the treatment of HCV infection. Herein we describe our continued research efforts around the alkyl “Z group” modification of the tetracyclic indole-based NS5A